IL17A and chronic obstructive pulmonary disease: In bronchial epithelial cell lines, the researchers showed that interleukin-17A induces the expression of TSLP, whereas an existing bronchodilatator anticholinerc drug, usually used to treat COPD, reduces TSLP levels.